爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

caduceus pharma ltd - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - cisplatin - concentrate for soln for inf - 0.5 micromol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

ebewe pharma ges.m.b.h nfg. kg - cisplatin - concentrate for soln for inf - 1 micromol

爱尔兰 - 英文 - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - cisplatin - concentrate for soln for inf - 1 mg/ml - platinum compounds

英国 - 英文 - myHealthbox

cipla (eu) limited - cisplatin. - concentrate for solution for infusion - 1mg/ml - other antineoplastic agents, pla - for the treatment of: • advanced or metastatic testicular cancer • advanced or metastatic ovarian cancer • advanced or metastatic bladder carcinoma • advanced or metastatic squamous cell carcinoma of the head and neck • advanced or metastatic non-small cell lung carcinoma • advanced or metastatic small cell lung carcinoma

美国 - 英文 - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol-aq (cisplatin injection) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol-aq and cyclophosphamide. platinol-aq, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol-aq therapy. platinol-aq is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol-aq is contraindicated in patients with preexisting renal impairme

美国 - 英文 - NLM (National Library of Medicine)

corden pharma latina s.p.a. - cisplatin (unii: q20q21q62j) (cisplatin - unii:q20q21q62j) - cisplatin 1 mg in 1 ml - platinol (cisplatin for injection, usp) is indicated as therapy to be employed as follows: in established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. in established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. an established combination consists of platinol and cyclophosphamide. platinol, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received platinol therapy. platinol is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. platinol is contraindicated in patients with preexisting renal impairment. plati

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

hospira uk ltd - cisplatin - solution for infusion - 1mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cisplatin - solution for infusion - 1mg/1ml

英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - cisplatin - solution for infusion - 1mg/1ml